by
Steven Ertelt
LifeNews.com Editor
April 11,
2007
Washington,
DC (LifeNews.com) -- While scientists in Brazil have shown that
adult stem cell treatments can help patients with diabetes to be insulin
free, leading diabetes groups in the U.S., which are heavily funding
lobbying efforts to get the Senate to approve a bill to force taxpayers
to fund embryonic stem cell research, wouldn't put money behind the
study.
Publishing their findings in the most recent issue of the Journal of the American Medical Association, the scientists found that adult stem cell treatments helped 14 of 15 patients became insulin free.
Dr. Richard Burt of Northwestern University's Feinberg School of Medicine in Chicago, worked with the scientists.
"It's the first time in the history of Type 1 diabetes where people have gone with no treatment whatsoever ... no medications at all, with normal blood sugars," he says of the groundbreaking study.
That would seem like a real miracle for the millions of Americans who suffer from diabetes.
However, the JAMA article lists the sources of funding for the study and the researchers involved had to get funds from a private corporation and the Brazilian Ministry of Health.
That's because the American Diabetes Association and the Juvenile Diabetes Research Foundation did not put amy money behind it and, instead, have spent countless funds lobbying Congress to fund embryonic stem cell research, which has yet to help any patients.
Emails to both organizations from LifeNews.com asking why they did not get involved with the Brazil diabetes study went unanswered.
Burt confirmed their non-participation, telling AP that they "were not interested in the approach."
In a statement given to LifeNews.com, Nikolas Nikas, the president of the Bioethics Defense Fund, lamented the lack of interest.
"It is unfortunate that this remarkable research was conducted in Brazil while in this country so much attention has been placed on embryo destructive research," he said.
"Embryo destructive research presents problems such as tumor formation and rejection issues for clinical applications and has not been proven safe or effective enough for human applications," he said.
"Meanwhile research like this demonstrates that ethical stem cells continue to present real tangible treatments for millions of Americans," Nikas concluded.
Related
web sites:
Bioethics Defense Fund - http://www.bdfund.org


